Praxis Precision Medicines, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Praxis Precision Medicines, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than almost all Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 665% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-2,264.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than almost all Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Praxis Precision Medicines, Inc. made a loss over the last year. Praxis Precision Medicines, Inc. owes $0.04 for every $1 it owns. Praxis Precision Medicines, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPraxis Precision Medicines, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.27The share price is 5.27 times Praxis Precision Medicines, Inc.'s book value per share, higher than 73% of Healthcare companies in United States.
Market cap
$7.1 BThe total market value of all of Praxis Precision Medicines, Inc.'s shares at today's price (share price × number of shares), larger than 87% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.3 BWhat Praxis Precision Medicines, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$48.03Net worth divided by the number of shares. The share price of $252.96 is 5.3 times this, which is the P/B above.
Return on equity (ROE)
-38.9%Praxis Precision Medicines, Inc. lost 38.9% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
Owes vs Owns
0.04×Praxis Precision Medicines, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Dividend yield
NonePraxis Precision Medicines, Inc. does not currently pay a dividend.
Profit growth
LossPraxis Precision Medicines, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashPraxis Precision Medicines, Inc. held $599 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Praxis Precision Medicines, Inc.: $7.1 B ÷ $1.3 B (30 Jun 2026) = 5.3.
What is Praxis Precision Medicines, Inc.'s return on equity?
Praxis Precision Medicines, Inc. lost 38.9% of its shareholders' money over the last year, higher than 56% of Healthcare companies in United States.
How much does Praxis Precision Medicines, Inc. owe compared with what it owns?
Praxis Precision Medicines, Inc. owes $0.04 for every $1 it owns (low), lower than 98% of Healthcare companies in United States.
Does Praxis Precision Medicines, Inc. pay a dividend?
No. Praxis Precision Medicines, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.